Quantcast
Last updated on April 18, 2014 at 7:29 EDT

Latest Neural Stem Cell Stories

2012-09-27 02:28:14

ROCKVILLE, Md., Sept. 27, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced it has been approved to commence a clinical trial to treat motor deficits due to ischemic stroke with its spinal cord stem cells (NSI-566) at BaYi Brain Hospital, in Beijing, China, through its subsidiary, Neuralstem China (Suzhou Neuralstem Biopharmaceutical Company, Ltd.). The trial approval includes a combined phase I/II design and will test direct injections into the brain of NSI-566, the same cell...

2012-09-19 16:57:24

Groundbreaking advancements described in Stem Cells and Development Researchers have successfully developed a stable population of neural crest cells derived from mice that can be grown in large quantities in the laboratory and that demonstrates the potential to develop into many different cell types needed throughout the body. This powerful new research tool for understanding stem cell biology and human development and disease is described in an article published in Stem Cells and...

2012-09-11 02:29:31

ROCKVILLE, Md., Sept. 11, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that Karl Johe, PhD, will give an update on the NSI-189 ongoing clinical trial in major depressive disorder (MDD) at the 6(th) Neurodegenerative Conditions Research and Development conference, September 13-14, in San Francisco, CA (http://www.gtcbio.com/index.php?option=com_conference&file=speaker&cn=5th%20Neurodegenerative&cid=37). NSI-189 is the lead compound in Neuralstem's neurogenic...

2012-09-10 10:26:27

ROCKVILLE, Md., Sept. 10, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the 2012 Rodman & Renshaw Annual Healthcare Conference on Tuesday, September 11 at 2:00 p.m. EDT, at The Waldorf=Astoria, Starlight South. Garr will discuss the company's opportunities and advancements in neural stem cell therapy and pharmaceuticals. He will be providing an update on ongoing clinical trials, including the recently completed ALS...

2012-09-06 23:01:43

Grafting stem cells from one part of the brain into another can restore important cognitive functions such as memory and mood after brain injury and also trigger the growth of new neurons, a U.S. research team has found. The study, published in the current issue of STEM CELLS Translational Medicine, was conducted by researchers from the Institute for Regenerative Medicine at Texas A&M Health Science Center, Duke University Medical Center and Veterans Affairs Medical Centers in Temple,...

2012-09-06 02:32:53

ROCKVILLE, Md., Sept. 6, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that it has granted the first licenses for use of its Spinal Cord Delivery Platform and Floating Cannula, for delivering therapeutic agents to the spinal cord, to Salt Lake City-based Q Therapeutics. This platform and cannula have been in use since 2010, in the recently completed Phase I ALS trial delivering Neuralstem's NSI-566 neural stem cells into the spinal cords of patients with amyotrophic lateral...

Could Learning Disabilities In Some Kids Be Prevented With Cancer Drug?
2012-08-29 11:01:08

U-M scientists stop abnormal brain cell growth in mice with neurofibromatosis using experimental tumor drug, make new discoveries in neural stem cells A drug originally developed to stop cancerous tumors may hold the potential to prevent abnormal brain cell growth and learning disabilities in some children, if they can be diagnosed early enough, a new animal study suggests. The surprising finding sets the stage for more research on how anti-tumor medication might be used to protect the...